


		LacZ $\alpha$ initiation codon			T3 priming site	
	M13 Reverse priming site					
201	CACACAGGAA	ACAGCTATGA	CCATGATTAC	GCCAAGCTCA	GAATTAACCC	TCCTAAAGG
	GTGTGTCCTT	TGTCGATACT	GGTACTAATG	CGGTTTCGAGT	CTTAATTGGG	AGTGATTTC
	Spe I	Pst I	Pme I	EcoR I		EcoR I Not I
261	GACTAGTCCT	GCAGGTTTAA	ACGAATTCGC	CCTT	PCR Product	AAGGGC
	CTGATCAGGA	CGTCCAAATT	TGCTTAAGCG	GGA		GAATTCGCGG
						TTCCCG
						CTTAAGCGCC
		T7 priming site			M13 Forward (-20) priming site	
311	CCGCTAAATT	CAATTCGCCC	TATAGTGAGT	CGTATTACAA	TTCCTGGCC	GTCGTTTTAC
	GGCGATTAA	GTTAAGCGGG	ATATCACTCA	GCATAATGTT	AAGTGACCGG	CAGCAAAATG



#### Comments for pCR®4-TOPO® 3956 nucleotides

*lac* promoter region: bases 2-216  
 CAP binding site: bases 95-132  
 RNA polymerase binding site: bases 133-178  
 Lac repressor binding site: bases 179-199  
 Start of transcription: base 179  
 M13 Reverse priming site: bases 205-221  
 LacZ $\alpha$ -*ccdB* gene fusion: bases 217-810  
     LacZ $\alpha$  portion of fusion: bases 217-497  
     *ccdB* portion of fusion: bases 508-810  
 T3 priming site: bases 243-262  
 TOPO® Cloning site: bases 294-295  
 T7 priming site: bases 328-347  
 M13 Forward (-20) priming site: bases 355-370  
 Kanamycin promoter: bases 1021-1070  
 Kanamycin resistance gene: bases 1159-1953  
 Ampicillin (*bla*) resistance gene: bases 2203-3063 (c)  
 Ampicillin (*bla*) promoter: bases 3064-3160 (c)  
 pUC origin: bases 3161-3834  
 (c) = complementary strand